Whitehawk director granted options on 76K shares

A Whitehawk Therapeutics director received a three-year vesting stock option grant for 76,080 shares at a $4.19 exercise price.

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. (WHWK) reported that director Vijay K. Iyengar received a stock option grant on September 9, 2026. The award covers 76,080 shares of common stock at an exercise price of $4.19 per share, expiring on September 9, 2036, and is held directly.

According to the award terms, the option vests in 36 equal monthly installments, with one thirty-sixth of the shares vesting each month so that all shares are fully vested on the three-year anniversary of the September 9, 2026 grant date. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 76,080 shares

Grant/Award 1 txn

Insider Iyengar Vijay K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	76,080	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 76,080 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares subject to the option shall be fully vested on the three year anniversary of the grant date. The grant date is September 9, 2026.

Key Figures

Option grant size: 76,080 shares Exercise price: $4.19 per share Expiration date: September 9, 2036 +3 more

6 metrics

Option grant size 76,080 shares Shares of common stock underlying the stock option granted on September 9, 2026

Exercise price $4.19 per share Exercise price of the stock option covering 76,080 shares

Expiration date September 9, 2036 Expiration date of the granted stock option

Vesting period 3 years Option fully vests on the three-year anniversary of the September 9, 2026 grant date

Monthly vesting fraction 1/36th of shares per month Portion of the option that vests each month, subject to continued service

Shares held in option after grant 76,080 shares Total shares subject to the option reported as held following the transaction

Key Terms

Service Provider, Equity Incentive Plan, grant date

3 terms

Service Provider regulatory

"Subject to the Reporting Person continuing to be a Service Provider"

Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

grant date financial

"such that all shares subject to the option shall be fully vested on the three year anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did WHWK report for Vijay K. Iyengar?

WHWK reported that director Vijay K. Iyengar received a stock option grant on September 9, 2026 for 76,080 shares of common stock, held directly, as a compensation-related award rather than a market purchase.

How many WHWK shares are covered by the new option grant and at what exercise price?

The option grant covers 76,080 shares of Whitehawk Therapeutics common stock, with an exercise price of $4.19 per share. These options give the right to buy the shares at that price if and when they vest and are exercised.

What is the vesting schedule of Vijay K. Iyengar’s WHWK stock option grant?

The option vests over three years. One thirty-sixth (1/36th) of the shares vests on a monthly basis following the September 9, 2026 grant date, so that all 76,080 shares are fully vested on the three-year anniversary of that date.

When do Vijay K. Iyengar’s newly granted WHWK options expire?

The stock options granted to Vijay K. Iyengar on September 9, 2026 expire on September 9, 2036. After that expiration date, any unexercised portion of the option can no longer be exercised.

Is the WHWK option grant to Vijay K. Iyengar tied to continued service?

Yes. Vesting is conditioned on Iyengar continuing to be a Service Provider, as defined in Whitehawk Therapeutics’ 2021 Equity Incentive Plan, through each applicable vesting date, with monthly vesting over three years from the September 9, 2026 grant date.

Was the WHWK option grant to Vijay K. Iyengar made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this option grant to Vijay K. Iyengar.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:05 PM Accepted by SEC EDGAR 09/11/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iyengar Vijay K

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BLDG, 11 FL

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.19	09/09/2026		A		76,080		(1)	09/09/2036	Common Stock	76,080	$0	76,080	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares subject to the option shall be fully vested on the three year anniversary of the grant date. The grant date is September 9, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)